<DOC>
	<DOCNO>NCT00659321</DOCNO>
	<brief_summary>Placebo control evaluation effectiveness nicotine acid treatment postprandial dyslipidemia patient metabolic syndrome . Nicotine acid decrease postprandial hyperlipidaemia patient metabolic syndrome reduces low-grade inflammation risk atherosclerosis .</brief_summary>
	<brief_title>Efficacy Nicotine Acid Dyslipidaemia Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>dyslipidemia ( triglycerides &gt; = 150 mg/dl and/or decrease level HDLcholesterol &lt; 40 mg/dl men &lt; 50 mg/dl woman ) component metabolic syndrome : Hypertension : blood pressure &gt; = 130/85 mmHg or/and Hyperglycemia : fasting plasma glucose &gt; = 100 mg/dl or/and 2 hour plasma glucose 75g glucose load ( OGTT ) &gt; = 140 mg/dl or/and Obesity : waist circumference &gt; 102 cm men &gt; 88 cm woman Contraindication incompatibility nicotine acid Patients ulcus ventriculus ulcus duodeni Intake lipid lower drug &lt; 6 week randomization therapy type 2 diabetes insulin , glitazones , acarbose one antidiabetic drug ( monotherapy metformin sulfonyl urea permit ) acceptable therapy diabetes level HbA1C &gt; =8.0 % cardiovascular event last 6 month chronic inflammatory disease ( lupus erythematodes , arthritis , morbus Crohn colitis ulcerosa ) ALAT elevation 2.5 time normal limit pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>